Evidence map›Paper›PMID 40413212›Full record

ReviewNPJ vaccines2025

Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19.

Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Courage Idahor, Petra Mariaria, Favour Peters, Raolat Adenike Salami, Olajide Ojo, Emmanuel Nwaeze, Owolabi Abdullahi and 1 more

RetractedAbstract readReviewRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Adewunmi AkingbolaDepartment of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire England, Cambridge, UK.ORCID http://orcid.org/0000-0001-7245-0340
Abiodun AdegbesanAfrican Cancer Institute, Department of Global Health, Stellenbosch University, Cape Town, South Africa.ORCID http://orcid.org/0000-0001-9478-5360
Kolade AdegokeFaculty of Clinical Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID http://orcid.org/0009-0006-1509-0274
Courage IdahorNottingham University Hospitals NHS Trust, Nottingham, UK.ORCID http://orcid.org/0000-0002-5938-4817
Petra MariariaDepartment of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire England, Cambridge, UK.
Favour PetersDepartment of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire England, Cambridge, UK.
Raolat Adenike SalamiAfe Babalola University, Ekiti state, Nigeria.ORCID http://orcid.org/0009-0004-1877-8205
Olajide OjoUniversity of West England, Coldharbour Ln, Stoke Gifford, Bristol, UK.
Emmanuel NwaezeDepartment of community Health, Lagos State University College of Medicine, Ikeja Lagos, Nigeria.
Owolabi AbdullahiDepartment of Medicine, Faculty of Clinical Sciences, Bayero University, Kano state, Nigeria.ORCID http://orcid.org/0009-0005-1241-4301
Joel ChukuDepartment of Medicine, V.N Karazin Kharkiv National University, Svobody Square, Kharkiv, Ukraine. chuku2016.6391200@student.karazin.ua.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.

Identifiers

PMID40413212
PMCPMC12103547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.